PDGFRA and gastrointestinal stromal tumor: Phase I testing (NAVIGATOR study, NCT02508532) has demonstrated notable efficacy for exon 18 PDGFRA mutant GIST (12), leading to FDA approval for the use of avapritinib in unresectable or metastatic PDGFRA exon 18 mutant GIST in January 2020.